GABA (oral supplement)

Endogenous brain neurotransmitter sold as a $0.10/dose dietary supplement. Oral GABA does not meaningfully cross the blood-brain barrier (Boonstra 2015, replicated for ~60 years). Any subjective effect is mostly placebo plus a minor peripheral / enteric-nervous-system signal that propagates to brain via vagus — real but weak, and outclassed by every other tool in Dylan's stack. SKIP-PERMANENT. If you want "calm," theanine + magnesium glycinate + glycine already do that work, with actual BBB-crossing molecules and better evidence. If you want a BBB-crossing GABAergic, that's picamilon's job.

GABA (γ-aminobutyric acid, 4-aminobutanoic acid) is the brain's primary inhibitory neurotransmitter. Endogenous CNS GABA — the kind your brain synthesizes from glutamate via glutamic acid decarboxylase (GAD) — binds two main receptor families:

• GABA-A receptors — pentameric ligand-gated chloride channels. Activation hyperpolarizes neurons (inhibition). This is the receptor family targeted by benzodiazepines (alprazolam, diazepam, etc., as positive allosteric modulators), z-drugs (zolpidem), alcohol (low-dose modulation), and barbiturates. GABA-A activation produces fast inhibitory postsynaptic potentials and, at high enough levels, sedation, anxiolysis, anticonvulsant action, and amnesia.
• GABA-B receptors — metabotropic G-protein-coupled receptors. Slower, longer-lasting inhibition via K⁺ channel opening + Ca²⁺ channel inhibition. Targeted by baclofen and (partially) phenibut. Effects: muscle relaxation, deeper anxiolysis, anti-craving, sedation at higher doses.

The pharmacology of endogenous GABA at these receptors is uncontroversial and well-characterized. The problem with oral GABA-the-supplement is upstream of all of that: the molecule has to actually reach the brain to do anything central, and it largely doesn't.

The BBB problem (the central pharmacological fact)

The blood-brain barrier is a layer of tightly junctioned endothelial cells lining cerebral capillaries that excludes most polar / hydrophilic molecules unless they have a dedicated transporter. GABA is small (MW 103) but highly polar (zwitterionic at physiologic pH — both an amino and a carboxyl group ionized), which gives it terrible passive diffusion across the lipid-rich BBB endothelium. The classical animal work establishing this:

• Van Gelder & Elliott (1958) — original demonstration in rats that radiolabeled GABA injected systemically gives extremely low CSF/brain levels relative to plasma.
• Kuriyama & Sze (1971) — confirmed BBB exclusion of peripheral GABA in rats.
• Al-Sarraf (2002) — quantitative work in rats showing that increasing systemic GABA administration 1,250-fold produces only a 30-fold increase in CSF GABA. That ratio (1,250:30 ≈ 42:1) tells you the BBB is doing roughly two orders of magnitude of exclusion. To get a "pharmacological" central GABA increase from oral dosing, you'd need to take supraphysiologic doses that aren't safe or feasible.
• Shyamaladevi et al. (2002) — same general result with refinements.

The Boonstra et al. 2015 review in Frontiers in Psychology ("Neurotransmitters as food supplements: the effects of GABA on brain and behavior") is the canonical Western reference for this position. Boonstra's framing: "It has long been thought that GABA is unable to cross the blood-brain barrier, but the studies that have assessed this issue are often contradictory and range widely in their employed methods... Any veridical effects of GABA food supplements on brain and cognition might be exerted through BBB passage or, more indirectly, via an effect on the enteric nervous system."

The conclusion: the BBB-crossing route is at best minor; the dominant alternative explanation is peripheral.

The 2024-2025 ENS / vagus revision (the part that's been overstated)

A wave of 2024 papers in the gut-brain-axis space (Tandfonline 2024 GABA + Alzheimer review, Frontiers 2024 GABA + intestinal epithelial cells, Brain 2024 "From bugs to brain" GABA review) has rebuilt the case that microbiota-derived and dietary GABA can affect brain function via the enteric nervous system and vagus nerve — without ever crossing the BBB. The mechanism, condensed:

1. GABA in the gut (from supplement, food, or Lactobacillus / Bifidobacterium fermentation) activates GABA receptors on enteric neurons in the myenteric plexus (~5-8% of myenteric neurons are GABAergic).
2. ENS signaling propagates to vagal afferent fibers, which project to the nucleus tractus solitarius (NTS) in the brainstem.
3. NTS relays to hypothalamic and limbic structures (PVN, amygdala, locus coeruleus) and modulates norepinephrine release and HPA-axis tone.
4. Net result: a modest peripheral-origin signal that reaches central anxiety circuits without ever requiring oral GABA to cross the BBB.

This is mechanistically real, and it's the strongest defense oral-GABA proponents have. But:

• The signal is weak — vagal afferents carry many competing signals (stretch, cytokines, hormones, fatty acids, other neurotransmitters), and exogenous oral GABA is one of many inputs.
• The signal is slow and unspecific — vagal modulation of HPA tone is more like a thermostat nudge than a fast pharmacological effect.
• The signal is outclassed by other tools that hit the same axis better: theanine (BBB-crossing alpha-wave inducer + GABA bump in animals), magnesium glycinate (BBB-crossing NMDA gatekeeper + glycinergic), glycine itself (BBB-crossing inhibitory co-agonist at NMDA), taurine (BBB-crossing GABA-A δ-subunit agonist + osmoregulator), tryptophan (5-HT precursor with BBB crossing).
• The signal is not what most users mean when they say "GABA worked for me." Most consumer expectation is that the molecule reaches the brain. It doesn't.

Marginal BBB-crossing claim (the part that's been promoted but is shaky)

A subset of recent reviews (e.g., 2024 Nutraceuticals review) raises the possibility that GABA crosses the BBB via specific amino-acid transporters like LAT1 / LAT2 (large neutral amino acid transporters). This is true in the sense that any mammalian transporter has some affinity profile, but quantitatively the transport is trivial at supplement doses, and the LAT family preferentially handles other amino acids (leucine, phenylalanine, tryptophan) which outcompete GABA for the transporter. In practice this pathway is not pharmacologically meaningful at 100-1000 mg oral doses.

Disease-state and inflammation modulation of the BBB (e.g., hyperammonemia, sepsis, neuroinflammation, traumatic brain injury) can transiently increase BBB permeability — but Dylan does not have any of these conditions, and even if he did, the appropriate intervention is not "take more GABA supplement."

Synthetic GABA vs PharmaGABA (fermented) — same BBB problem

PharmaGABA® is a branded ingredient produced by fermentation of Lactobacillus hilgardii (the same organism that ferments kimchi). Marketing positions it as "natural" GABA with superior bioavailability, alpha-wave induction, and subjective relaxation effects. Two things are true and one isn't:

• TRUE: PharmaGABA is structurally identical to synthetic GABA at the molecular level. It's the same molecule.
• TRUE: A handful of small Japanese studies (notably the often-cited 2006 Abdou et al., n=13 healthy young adults, 100 mg PharmaGABA vs. placebo) showed alpha-wave EEG increase and subjective lower stress on cognitive tasks. Thorne markets PharmaGABA-100/250 on the basis of these findings.
• NOT TRUE: PharmaGABA penetrates the BBB any better than synthetic GABA. Same molecule, same BBB exclusion. No independent human pharmacokinetic study has shown differential BBB transport for fermented vs. synthetic GABA. The "natural is better" claim is marketing, not pharmacology.

The alpha-wave findings from PharmaGABA studies, to the extent they're real, are most parsimoniously explained by the ENS-vagus pathway above — which works just as well with synthetic GABA. The only mechanism by which fermented GABA could plausibly outperform synthetic is if the fermentation process delivers ancillary bioactive compounds from L. hilgardii (peptides, exopolysaccharides, postbiotic metabolites) that have their own activity. There's no robust evidence this is what's happening; it's hand-waving.

Summary of mechanism

• Oral GABA hits gut GABA receptors → vagal afferents → modest CNS signal. This is real but weak.
• Oral GABA does NOT meaningfully cross the BBB at supplement doses (20 to 60 years of replicated rat/human work).
• Any subjective "calm" at 100-1000 mg oral GABA is some combination of: (1) placebo expectation, (2) ENS-vagus modulation, (3) peripheral autonomic effects (mild BP drop, mild flushing).
• Fermented (PharmaGABA) and synthetic GABA are pharmacologically equivalent.
• This is not a useful CNS pharmacological tool.